Jon Stonehouse Net Worth

The estimated Net Worth of Jon P Stonehouse is at least 11.2 百万$ dollars as of 13 May 2024. Mr. Stonehouse owns over 30,000 units of Biocryst Pharmaceuticals stock worth over 8,717,662$ and over the last 18 years he sold BCRX stock worth over 166,696$. In addition, he makes 2,284,300$ as President、 Chief Executive Officer、 Director at Biocryst Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Stonehouse BCRX stock SEC Form 4 insiders trading

Jon has made over 32 trades of the Biocryst Pharmaceuticals stock since 2007, according to the Form 4 filled with the SEC. Most recently he bought 30,000 units of BCRX stock worth 166,500$ on 13 May 2024.

The largest trade he's ever made was exercising 297,573 units of Biocryst Pharmaceuticals stock on 1 December 2022 worth over 422,554$. On average, Jon trades about 19,218 units every 70 days since 2007. As of 13 May 2024 he still owns at least 1,127,770 units of Biocryst Pharmaceuticals stock.

You can see the complete history of Mr. Stonehouse stock trades at the bottom of the page.

Jon Stonehouse biography

Jon P. Stonehouse serves as President, Chief Executive Officer, Director of the Company. He joined BioCryst in January 2007 as Chief Executive Officer and Director. He was also named President in July 2007. Prior to joining the Company, he served as Senior Vice President of Corporate Development for Merck KGaA, a pharmaceutical company, since July 2002. His responsibilities included corporate mergers and aquisitions, global licensing and business development, corporate strategy and alliance management. Prior to joining Merck KGaA, Mr. Stonehouse held a variety of roles at Astra Merck/AstraZeneca. Mr. Stonehouse began his career in the pharmaceutical industry as a sales representative and held increasing sales leadership positions at Merck &Co., Inc. In 2008 and 2011, respectively, Mr. Stonehouse joined the Advisory Boards of Precision Biosciences, Inc., a private biotechnology company and Genscript, a private bioservices company. Also in December 2014, he joined the Board of Directors of Bellicum Pharmaceuticals, Inc., a publicly traded clinical stage biopharmaceutical company focused on novel cellular immunotherapies. Mr. Stonehouse earned his BS in Microbiology at the University of Minnesota. As Chief Executive Officer and President of BioCryst, Mr. Stonehouse brings to the Board an intimate knowledge of our business, and his executive experience in a variety of capacities at major pharmaceutical companies provides industry-specific operational experience that is beneficial to the Board.

What is the salary of Jon Stonehouse?

As the President、 Chief Executive Officer、 Director of Biocryst Pharmaceuticals, the total compensation of Jon Stonehouse at Biocryst Pharmaceuticals is 2,284,300$. There are no executives at Biocryst Pharmaceuticals getting paid more.

How old is Jon Stonehouse?

Jon Stonehouse is 59, he's been the President、 Chief Executive Officer、 Director of Biocryst Pharmaceuticals since 2007. There are 10 older and 11 younger executives at Biocryst Pharmaceuticals. The oldest executive at Biocryst Pharmaceuticals Inc. is Robert Ingram, 77, who is the Independent Chairman of the Board.

What's Jon Stonehouse's mailing address?

Jon's mailing address filed with the SEC is 4505 EMPEROR BLVD., SUITE 200, DURHAM, NC, 27703.

Insiders trading at Biocryst Pharmaceuticals

Over the last 24 years, insiders at Biocryst Pharmaceuticals have traded over 76,362,383$ worth of Biocryst Pharmaceuticals stock and bought 4,042,003 units worth 20,848,654$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Brothers Life Sciences Capi...、Carl L Gordon. On average, Biocryst Pharmaceuticals executives and independent directors trade stock every 31 days with the average trade being worth of 542,329$. The most recent stock trade was executed by Amy E Mc Kee on 24 June 2024, trading 8,600 units of BCRX stock currently worth 54,352$.

What does Biocryst Pharmaceuticals do?

biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.

Complete history of Mr. Stonehouse stock trades at Bellicum Pharmaceuticals Inc、Biocryst Pharmaceuticals

Biocryst Pharmaceuticals executives and stock owners

Biocryst Pharmaceuticals executives and other stock owners filed with the SEC include:

• Jon Stonehouse,
  President, Chief Executive Officer, Director
• Megan Sniecinski,
  Senior Vice President, Chief Business Officer
• Alane Barnes,
  Senior Vice President, Chief Legal Officer and Corporate Secretary
• Jon P. Stonehouse,
  CEO, Pres & Exec. Director
• Yarlagadda Babu,
  Senior Vice President - Drug Discovery
• William Sheridan,
  Senior Vice President, Chief Medical Officer
• Dr. William P. Sheridan,
  Chief Medical Officer & Sr. VP
• Dr. Yarlagadda S. Babu,
  Chief Discovery Officer
• Stephen Aselage,
  Independent Director
• Robert Ingram,
  Independent Chairman of the Board
• Kenneth Lee,
  Independent Director
• Nancy Hutson,
  Independent Director
• George Abercrombie,
  Independent Director
• Theresa Heggie,
  Independent Director
• Helen Thackray,
  Independent Director
• Dr. Helen M. Thackray FAAP, M.D.,
  Chief R&D Officer
• Anthony Doyle,
  Chief Financial Officer, Senior Vice President
• Alan Levin,
  Independent Director
• Charles Gayer,
  Senior Vice President, Chief Commercial Officer
• Allen Hodge,
  Vice President and General Manager for the United States
• Michael Jones,
  Executive Director - Finance, Principal Accounting Officer
• Alane P. Barnes,
  Sr. VP, Chief Legal Officer & Corp. Sec.
• Michael L. Jones,
  Exec. Director of Fin. & Principal Accounting Officer
• Dr. Elliott T. Berger,
  Sr. VP of Regulatory Affairs
• Robert C. Stoner,
  VP of HR
• John D. Bluth,
  Sr. VP of Investor Relations & Corp. Communications
• Anthony Doyle,
  Sr. VP & CFO
• Sanj K Patel,
  Director
• Stanley C Erck,
  Director
• Fred E Cohen,
  Director
• Lynne Powell,
  Senior VP - CCO
• Thomas R Ii Staab,
  Senior Vice President and CFO
• Bros. Advisors Lp Baker Bro...,
  
• John L Higgins,
  Director
• Felix Baker Bros. Investmen...,
  
• Zola P Horovitz,
  Director
• Robert S Lowrey,
  Controller, PAO
• Steven K Galson,
  Director
• Steve Aselage,
  Director
• Brothers Life Sciences Capi...,
  
• David Mc Cullough,
  VP
• Bros. Capital (Gp), Llcbake...,
  
• Stephen R Biggar,
  Director
• Stuart Grant,
  SR VP & CFO
• Beth C Seidenberg,
  Director
• William W Featheringill,
  Director
• / Tisch Capital (Gp), Llcba...,
  
• Biotech Capital (Gp), Llcba...,
  
• Capital (Gp), Llcbaker Juli...,
  
• Mike Mills,
  Principal Accounting Officer
• Partners L P/Ilbiotechnolog...,
  
• Carl L Gordon,
  Director
• Charles E Bugg,
  CEO
• J Claude Bennett,
  President
• John A Montgomery,
  Director
• Jonathan M Nugent,
  VP Corp Communications
• W James Alexander,
  SR. VP, Chief Medical Officer
• Randall B Riggs,
  VP Business Development
• Michael A Darwin,
  CFO
• Randolph C Steer,
  Director
• Joseph H Jr Sherrill,
  Director
• William M Iii Spencer,
  Director
• Charles A Sanders,
  Director
• Peder Jensen,
  Director
• Amy E Mc Kee,
  Director
• Machelle Sanders,
  Director
• Vincent Milano,
  Director